4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Safety and Efficacy of Live Viral Vaccines in Patients With Cartilage-Hair Hypoplasia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Live viral vaccines are generally contraindicated in patients with combined immunodeficiency including cartilage-hair hypoplasia (CHH); however, they may be tolerated in milder syndromes. We evaluated the safety and efficacy of live viral vaccines in patients with CHH.

          Methods

          We analyzed hospital and immunization records of 104 patients with CHH and measured serum antibodies to measles, mumps, rubella, and varicella zoster virus (VZV) in all patients who agreed to blood sampling ( n = 50). We conducted a clinical trial ( ClinicalTrials.gov identifier: NCT02383797) of live VZV vaccine on five subjects with CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and were seronegative for VZV; humoral and cellular immunologic responses were assessed post-immunization.

          Results

          A large proportion of patients have been immunized with live viral vaccines, including measles-mumps-rubella (MMR) ( n = 40, 38%) and VZV ( n = 10, 10%) vaccines, with no serious adverse events. Of the 50 patients tested for antibodies, previous immunization has been documented with MMR ( n = 22), rubella ( n = 2) and measles ( n = 1) vaccines. Patients with CHH demonstrated seropositivity rates of 96%/75%/91% to measles, mumps and rubella, respectively, measured at a medium of 24 years post-immunization. Clinical trial participants developed humoral and cellular responses to VZV vaccine. One trial participant developed post-immunization rash and knee swelling, both resolved without treatment.

          Conclusion

          No serious adverse events have been recorded after immunization with live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular immune response to live viral vaccines. Immunization with live vaccines may be considered in selected CHH patients with no or clinically mild immunodeficiency.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia.

          The recessively inherited developmental disorder, cartilage-hair hypoplasia (CHH) is highly pleiotropic with manifestations including short stature, defective cellular immunity, and predisposition to several cancers. The endoribonuclease RNase MRP consists of an RNA molecule bound to several proteins. It has at least two functions, namely, cleavage of RNA in mitochondrial DNA synthesis and nucleolar cleaving of pre-rRNA. We describe numerous mutations in the untranslated RMRP gene that cosegregate with the CHH phenotype. Insertion mutations immediately upstream of the coding sequence silence transcription while mutations in the transcribed region do not. The association of protein subunits with RNA appears unaltered. We conclude that mutations in RMRP cause CHH by disrupting a function of RNase MRP RNA that affects multiple organ systems.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses

            Vaccines play a vital role in protecting our communities against infectious disease. Unfortunately, some vaccines provide only partial protection or in some cases vaccine-mediated immunity may wane rapidly, resulting in either increased susceptibility to that disease or a requirement for more booster vaccinations in order to maintain immunity above a protective level. The durability of antibody responses after infection or vaccination appears to be intrinsically determined by the structural biology of the antigen, with multivalent protein antigens often providing more long-lived immunity than monovalent antigens. This forms the basis for the Imprinted Lifespan model describing the differential survival of long-lived plasma cell populations. There are, however, exceptions to this rule with examples of highly attenuated live virus vaccines that are rapidly cleared and elicit only short-lived immunity despite the expression of multivalent surface epitopes. These exceptions have led to the concept that multivalency alone may not reliably determine the duration of protective humoral immune responses unless a minimum number of long-lived plasma cells are generated by reaching an appropriate antigenic threshold of B cell stimulation. Examples of long-term and in some cases, potentially lifelong antibody responses following immunization against human papilloma virus (HPV), Japanese encephalitis virus (JEV), Hepatitis B virus (HBV), and Hepatitis A virus (HAV) provide several lessons in understanding durable serological memory in human subjects. Moreover, studies involving influenza vaccination provide the unique opportunity to compare the durability of hemagglutinin (HA)-specific antibody titers mounted in response to antigenically repetitive whole virus (i.e., multivalent HA), or detergent-disrupted “split” virus, in comparison to the long-term immune responses induced by natural influenza infection. Here, we discuss the underlying mechanisms that may be associated with the induction of protective immunity by long-lived plasma cells and their importance in future vaccine design.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.

              Post-transcriptional processing of some long non-coding RNAs (lncRNAs) reveals that they are a source of miRNAs. We show that the 268-nt non-coding RNA component of mitochondrial RNA processing endoribonuclease, (RNase MRP), is the source of at least two short (∼20 nt) RNAs designated RMRP-S1 and RMRP-S2, which function as miRNAs. Point mutations in RNase MRP cause human cartilage-hair hypoplasia (CHH), and several disease-causing mutations map to RMRP-S1 and -S2. SHAPE chemical probing identified two alternative secondary structures altered by disease mutations. RMRP-S1 and -S2 are significantly reduced in two fibroblast cell lines and a B-cell line derived from CHH patients. Tests of gene regulatory activity of RMRP-S1 and -S2 identified over 900 genes that were significantly regulated, of which over 75% were down-regulated, and 90% contained target sites with seed complements of RMRP-S1 and -S2 predominantly in their 3' UTRs. Pathway analysis identified regulated genes that function in skeletal development, hair development and hematopoietic cell differentiation including PTCH2 and SOX4 among others, linked to major CHH phenotypes. Also, genes associated with alternative RNA splicing, cell proliferation and differentiation were highly targeted. Therefore, alterations RMRP-S1 and -S2, caused by point mutations in RMRP, are strongly implicated in the molecular mechanism of CHH.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                11 August 2020
                2020
                : 11
                : 2020
                Affiliations
                [1] 1Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital , Helsinki, Finland
                [2] 2Folkhälsan Research Center, Institute of Genetics , Helsinki, Finland
                [3] 3Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki , Helsinki, Finland
                [4] 4Translational Immunology Research Program, University of Helsinki , Helsinki, Finland
                [5] 5Children’s Hospital, Clinicum, University of Helsinki , Helsinki, Finland
                [6] 6Department of Pediatrics and Adolescents, Turku University Hospital, University of Turku , Turku, Finland
                [7] 7Department of Pediatrics, Kymenlaakso Central Hospital , Kotka, Finland
                [8] 8Helsinki University Hospital, HUSLAB, Division of Clinical Microbiology , Helsinki, Finland
                [9] 9Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet , Stockholm, Sweden
                [10] 10Department of Clinical Genetics, Karolinska University Hospital , Stockholm, Sweden
                Author notes

                Edited by: Yu Lung Lau, The University of Hong Kong, Hong Kong

                Reviewed by: Taizo Wada, Kanazawa University, Japan; Surjit Singh, Post Graduate Institute of Medical Education and Research (PGIMER), India

                This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2020.02020
                7432140
                32849667
                ea87d001-a173-454b-84fe-28de37fa0ae6
                Copyright © 2020 Vakkilainen, Kleino, Honkanen, Salo, Kainulainen, Gräsbeck, Kekäläinen, Mäkitie and Klemetti.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 10 June 2020
                : 27 July 2020
                Page count
                Figures: 2, Tables: 3, Equations: 0, References: 28, Pages: 8, Words: 0
                Categories
                Immunology
                Original Research

                Immunology
                clinical trial,combined immunodeficiency,immunization,mmr,rmrp,vaccination,varicella zoster virus

                Comments

                Comment on this article